Vaxcyte Historical Balance Sheet

PCVX Stock

USD 91.70 3.16 3.57%

Trend analysis of Vaxcyte balance sheet accounts such as Other Liabilities of 7.7 K, Net Tangible Assets of 1.2 B, Accounts Payable of 10.8 M or Cash of 290.5 M provides information on Vaxcyte's total assets, liabilities, and equity, which is the actual value of Vaxcyte to its prevalent stockholders. By breaking down trends over time using Vaxcyte balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Vaxcyte latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vaxcyte is a good buy for the upcoming year.

Vaxcyte Inventory

(5.85 Million)

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Vaxcyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

About Vaxcyte Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Vaxcyte at a specified time, usually calculated after every quarter, six months, or one year. Vaxcyte Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Vaxcyte and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Vaxcyte currently owns. An asset can also be divided into two categories, current and non-current.

Vaxcyte Balance Sheet Chart

At this time, Vaxcyte's Property Plant And Equipment Net is fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 327.6 M in 2024, whereas Other Liabilities is likely to drop 7,695 in 2024.

Other Current Liab Total Current Liabilities Other Liab Property Plant Equipment Non Current Assets Total Common Stock Total Equity

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Vaxcyte balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Vaxcyte are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most accounts from Vaxcyte's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Vaxcyte current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Vaxcyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.At this time, Vaxcyte's Property Plant And Equipment Net is fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 327.6 M in 2024, whereas Other Liabilities is likely to drop 7,695 in 2024.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	11.4M	18.9M	116.5M	122.4M
Total Assets	324.3M	1.0B	1.4B	1.5B

Other Current Liab Total Assets

Vaxcyte balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Long Term Debt Total	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Common Stock Total Equity
Total Assets		0.92	0.95	0.99	-0.94	0.99	-0.99	0.54	0.73	0.2	-0.73	0.99	0.86	-0.73	0.88	0.52	1.0	0.96	0.87	0.85	0.94	-0.67	-0.76	0.93	0.91	0.76
Other Current Liab	0.92		0.99	0.9	-0.79	0.87	-0.94	0.45	0.44	-0.12	-0.6	0.88	0.78	-0.6	0.74	0.58	0.88	0.84	0.76	0.73	0.98	-0.53	-0.48	0.99	0.99	0.58
Total Current Liabilities	0.95	0.99		0.93	-0.85	0.91	-0.96	0.56	0.53	-0.04	-0.68	0.92	0.82	-0.68	0.83	0.56	0.92	0.9	0.79	0.8	0.97	-0.61	-0.56	0.97	0.97	0.68
Total Stockholder Equity	0.99	0.9	0.93		-0.96	1.0	-0.98	0.54	0.75	0.23	-0.69	0.99	0.84	-0.69	0.89	0.42	0.99	0.97	0.88	0.86	0.92	-0.64	-0.78	0.91	0.89	0.77
Other Liab	-0.94	-0.79	-0.85	-0.96		-0.97	0.93	-0.6	-0.81	-0.44	0.74	-0.96	-0.84	0.74	-0.95	-0.36	-0.96	-0.98	-0.92	-0.92	-0.84	0.7	0.82	-0.81	-0.77	-0.88
Net Tangible Assets	0.99	0.87	0.91	1.0	-0.97		-0.97	0.57	0.8	0.3	-0.74	1.0	0.86	-0.74	0.91	0.44	1.0	0.98	0.89	0.88	0.9	-0.69	-0.82	0.88	0.85	0.81
Retained Earnings	-0.99	-0.94	-0.96	-0.98	0.93	-0.97		-0.51	-0.66	-0.19	0.75	-0.97	-0.89	0.75	-0.88	-0.57	-0.97	-0.96	-0.9	-0.86	-0.97	0.69	0.68	-0.95	-0.93	-0.76
Accounts Payable	0.54	0.45	0.56	0.54	-0.6	0.57	-0.51		0.62	0.11	-0.7	0.57	0.63	-0.7	0.74	0.3	0.57	0.66	0.36	0.72	0.37	-0.69	-0.61	0.37	0.36	0.77
Cash	0.73	0.44	0.53	0.75	-0.81	0.8	-0.66	0.62		0.53	-0.67	0.8	0.71	-0.67	0.74	0.3	0.8	0.77	0.61	0.72	0.46	-0.67	-0.99	0.43	0.39	0.76
Other Assets	0.2	-0.12	-0.04	0.23	-0.44	0.3	-0.19	0.11	0.53		-0.46	0.26	0.31	-0.46	0.45	-0.02	0.26	0.37	0.53	0.37	0.04	-0.5	-0.48	-0.04	-0.12	0.55
Long Term Debt	-0.73	-0.6	-0.68	-0.69	0.74	-0.74	0.75	-0.7	-0.67	-0.46		-0.74	-0.86	1.0	-0.86	-0.63	-0.75	-0.83	-0.74	-0.75	-0.62	1.0	0.65	-0.59	-0.55	-0.84
Cash And Short Term Investments	0.99	0.88	0.92	0.99	-0.96	1.0	-0.97	0.57	0.8	0.26	-0.74		0.87	-0.74	0.89	0.5	1.0	0.97	0.86	0.85	0.9	-0.69	-0.82	0.88	0.86	0.78
Common Stock Shares Outstanding	0.86	0.78	0.82	0.84	-0.84	0.86	-0.89	0.63	0.71	0.31	-0.86	0.87		-0.86	0.86	0.67	0.87	0.89	0.81	0.91	0.79	-0.84	-0.68	0.77	0.74	0.87
Long Term Debt Total	-0.73	-0.6	-0.68	-0.69	0.74	-0.74	0.75	-0.7	-0.67	-0.46	1.0	-0.74	-0.86		-0.86	-0.63	-0.75	-0.83	-0.74	-0.75	-0.62	1.0	0.65	-0.59	-0.55	-0.84
Capital Surpluse	0.88	0.74	0.83	0.89	-0.95	0.91	-0.88	0.74	0.74	0.45	-0.86	0.89	0.86	-0.86		0.4	0.89	0.97	0.89	0.93	0.79	-0.84	-0.74	0.75	0.71	0.95
Total Liab	0.52	0.58	0.56	0.42	-0.36	0.44	-0.57	0.3	0.3	-0.02	-0.63	0.5	0.67	-0.63	0.4		0.5	0.46	0.41	0.41	0.53	-0.6	-0.26	0.54	0.54	0.37
Total Current Assets	1.0	0.88	0.92	0.99	-0.96	1.0	-0.97	0.57	0.8	0.26	-0.75	1.0	0.87	-0.75	0.89	0.5		0.97	0.87	0.86	0.9	-0.7	-0.82	0.88	0.86	0.78
Common Stock	0.96	0.84	0.9	0.97	-0.98	0.98	-0.96	0.66	0.77	0.37	-0.83	0.97	0.89	-0.83	0.97	0.46	0.97		0.91	0.92	0.88	-0.79	-0.78	0.85	0.82	0.89
Property Plant Equipment	0.87	0.76	0.79	0.88	-0.92	0.89	-0.9	0.36	0.61	0.53	-0.74	0.86	0.81	-0.74	0.89	0.41	0.87	0.91		0.83	0.87	-0.71	-0.61	0.82	0.77	0.8
Short Long Term Debt Total	0.85	0.73	0.8	0.86	-0.92	0.88	-0.86	0.72	0.72	0.37	-0.75	0.85	0.91	-0.75	0.93	0.41	0.86	0.92	0.83		0.77	-0.72	-0.7	0.74	0.71	0.96
Property Plant And Equipment Net	0.94	0.98	0.97	0.92	-0.84	0.9	-0.97	0.37	0.46	0.04	-0.62	0.9	0.79	-0.62	0.79	0.53	0.9	0.88	0.87	0.77		-0.55	-0.49	1.0	0.99	0.63
Current Deferred Revenue	-0.67	-0.53	-0.61	-0.64	0.7	-0.69	0.69	-0.69	-0.67	-0.5	1.0	-0.69	-0.84	1.0	-0.84	-0.6	-0.7	-0.79	-0.71	-0.72	-0.55		0.64	-0.52	-0.47	-0.84
Net Debt	-0.76	-0.48	-0.56	-0.78	0.82	-0.82	0.68	-0.61	-0.99	-0.48	0.65	-0.82	-0.68	0.65	-0.74	-0.26	-0.82	-0.78	-0.61	-0.7	-0.49	0.64		-0.46	-0.43	-0.73
Non Current Assets Total	0.93	0.99	0.97	0.91	-0.81	0.88	-0.95	0.37	0.43	-0.04	-0.59	0.88	0.77	-0.59	0.75	0.54	0.88	0.85	0.82	0.74	1.0	-0.52	-0.46		1.0	0.59
Non Currrent Assets Other	0.91	0.99	0.97	0.89	-0.77	0.85	-0.93	0.36	0.39	-0.12	-0.55	0.86	0.74	-0.55	0.71	0.54	0.86	0.82	0.77	0.71	0.99	-0.47	-0.43	1.0		0.54
Common Stock Total Equity	0.76	0.58	0.68	0.77	-0.88	0.81	-0.76	0.77	0.76	0.55	-0.84	0.78	0.87	-0.84	0.95	0.37	0.78	0.89	0.8	0.96	0.63	-0.84	-0.73	0.59	0.54

Click cells to compare fundamentals

Vaxcyte Account Relationship Matchups

Vaxcyte balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	65.7M	392.8M	324.3M	1.0B	1.4B	1.5B
Other Current Liab	7.5M	17.1M	11.4M	18.9M	116.5M	122.4M
Total Current Liabilities	11.1M	46.9M	28.7M	40.5M	145.3M	152.6M
Total Stockholder Equity	(106.4M)	345.8M	284.0M	953.6M	1.2B	1.3B
Other Liab	259K	122K	96K	9K	8.1K	7.7K
Net Tangible Assets	(106.4M)	345.8M	284.0M	953.6M	1.1B	1.2B
Retained Earnings	(109.3M)	(198.6M)	(298.6M)	(522.1M)	(924.4M)	(878.2M)
Accounts Payable	3.4M	29.8M	6.8M	9.8M	14.6M	10.8M
Cash	59.0M	386.2M	69.0M	834.7M	397.5M	290.5M
Other Assets	584K	550K	5.0M	5.4M	1.0	0.95
Cash And Short Term Investments	59.0M	386.2M	246.0M	931.4M	1.1B	1.1B
Common Stock Shares Outstanding	48.9M	51.1M	51.9M	64.9M	97.2M	57.4M
Capital Surpluse	1.3M	3.0M	544.4M	582.8M	670.3M	703.8M
Total Liab	172.1M	47.0M	40.3M	52.6M	167.4M	96.9M
Total Current Assets	61.7M	389.0M	256.3M	942.6M	1.1B	1.2B
Common Stock	7K	54K	56K	82K	98K	102.9K
Property Plant Equipment	3.4M	3.3M	35.9M	31.6M	36.4M	38.2M
Property Plant And Equipment Net	3.4M	3.3M	35.9M	31.6M	110.6M	116.2M
Net Debt	(58.8M)	(386.2M)	(52.2M)	(816.7M)	(368.2M)	(386.6M)
Non Current Assets Total	4.0M	3.8M	68.0M	63.6M	312.0M	327.6M
Non Currrent Assets Other	584K	550K	5.0M	5.4M	38.7M	40.6M
Liabilities And Stockholders Equity	65.7M	392.8M	324.3M	1.0B	1.4B	1.5B
Non Current Liabilities Total	161.0M	122K	11.6M	12.0M	22.1M	43.8M
Capital Lease Obligations	161K	0.0	16.8M	17.9M	29.2M	30.7M
Other Current Assets	2.7M	2.5M	9.2M	5.3M	15.7M	16.5M
Other Stockholder Equity	3.0M	151.5M	582.8M	1.5B	2.2B	2.3B
Net Invested Capital	(106.4M)	345.8M	284.0M	953.6M	1.2B	1.3B
Accumulated Other Comprehensive Income	(160.3M)	(392.8M)	(241K)	(361K)	179K	188.0K
Capital Stock	7K	54K	56K	82K	98K	55.6K
Non Current Liabilities Other	242K	112K	96K	9K	8.1K	7.7K
Net Working Capital	50.7M	342.1M	227.6M	902.0M	950.6M	998.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vaxcyte Historical Balance Sheet

Vaxcyte Inventory

(5.85 Million)

About Vaxcyte Balance Sheet Analysis

Vaxcyte Balance Sheet Chart

Total Current Liabilities

Non Current Assets Total

Common Stock Total Equity

Vaxcyte balance sheet Correlations

Vaxcyte Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vaxcyte balance sheet Accounts

Also Currently Popular

Additional Tools for Vaxcyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Net Tangible Assets
Total Current Assets	+ 1.0	Net Tangible Assets
Long Term Debt Total	+ 1.0	Long Term Debt
Current Deferred Revenue	+ 1.0	Long Term Debt

Net Debt	- 0.99	Cash
Retained Earnings	- 0.99	Total Assets
Common Stock	- 0.98	Other Liab
Retained Earnings	- 0.98	Total Stockholder Equity
Property Plant And Equipment Net	- 0.97	Retained Earnings
Total Current Assets	- 0.97	Retained Earnings